Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 4253 is a short, ~22-nucleotide non-coding RNA encoded in the human genome. Like other microRNAs, it is processed from a primary transcript through Drosha and Dicer cleavage, producing a mature miRNA that is incorporated into the RNA-induced silencing complex (RISC). It acts as a negative regulator of gene expression, typically by binding imperfectly to target mRNAs to promote translational inhibition or destabilization. The broader microRNA family modulates various cellular pathways and disease states, but there is no literature specifically implicating MIR4253 in any particular disease, biological process, or as a druggable or therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 4253 (MIR4253).